Inhibiting oncogenic signaling by sorafenib activates PUMA via GSK3β and NF-κB to suppress tumor cell growth

Oncogene

Volumn 31, Issue 46, 2012, Pages 4848-4858

  Dudgeon, C ^a   Peng, R ^a   Wang, P ^a   Sebastiani, A ^a   Yu, J ^a   Zhang, L ^a  

^a UNIVERSITY OF PITTSBURGH CANCER INSTITUTE   (United States)

Author keywords

apoptosis; colon cancer; GSK3 ; NF B; PUMA; Sorafenib

Indexed keywords

BH3 PROTEIN; CASPASE; CISPLATIN; GLYCOGEN SYNTHASE KINASE 3BETA; I KAPPA B; IMMUNOGLOBULIN ENHANCER BINDING PROTEIN; OBATOCLAX; PROTEIN P53; PUMA PROTEIN; SORAFENIB; SYNAPTOTAGMIN I;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANTINEOPLASTIC ACTIVITY; APOPTOSIS; ARTICLE; BINDING SITE; CELL GROWTH; CHEMOSENSITIZATION; COLON CANCER; CONTROLLED STUDY; DRUG EFFECT; DRUG POTENTIATION; ENZYME ACTIVATION; FEMALE; GENETIC TRANSCRIPTION; HUMAN; HUMAN CELL; MOUSE; NONHUMAN; PRIORITY JOURNAL; PROMOTER REGION; PROTEIN DEGRADATION; PROTEIN PHOSPHORYLATION; PROTEIN TARGETING; PUMA GENE; SIGNAL TRANSDUCTION; TUMOR CELL;

ANIMALS; APOPTOSIS; APOPTOSIS REGULATORY PROTEINS; CASPASES; CELL LINE, TUMOR; CELL PROLIFERATION; EXTRACELLULAR SIGNAL-REGULATED MAP KINASES; FEMALE; GENES, RAS; GLYCOGEN SYNTHASE KINASE 3; HCT116 CELLS; HEP G2 CELLS; HT29 CELLS; HUMANS; MICE; MICE, NUDE; NF-KAPPA B; NIACINAMIDE; PHENYLUREA COMPOUNDS; PROMOTER REGIONS, GENETIC; PROTO-ONCOGENE PROTEINS; PROTO-ONCOGENE PROTEINS B-RAF; PROTO-ONCOGENE PROTEINS C-BCL-2; TRANSCRIPTION, GENETIC; TUMOR SUPPRESSOR PROTEIN P53; XENOGRAFT MODEL ANTITUMOR ASSAYS;

EID: 84869501760     PISSN: 09509232     EISSN: 14765594     Source Type: Journal    
DOI: 10.1038/onc.2011.644     Document Type: Article

References (51)

1. Vogelstein B, Kinzler KW. Cancer genes and the pathways they control. Nat Med 2004; 10:789-799. (Pubitemid 39070849)
2. Escudier B, Eisen T, Stadler WM, Szczylik C, Oudard S, Siebels M et al. Sorafenib in advanced clear-cell renal-cell carcinoma. N Engl J Med 2007; 356:125-134. (Pubitemid 46089673)
3. Llovet JM, Ricci S, Mazzaferro V, Hilgard P, Gane E, Blanc JF et al. Sorafenib in advanced hepatocellular carcinoma. N Engl J Med 2008; 359:378-390.
4. Green DR, Kroemer G. Pharmacological manipulation of cell death: clinical applications in sight? J Clin Invest 2005; 115:2610-2617. (Pubitemid 41434383)
5. Sordella R, Bell DW, Haber DA, Settleman J. Gefitinib-sensitizing EGFR mutations in lung cancer activate anti-apoptotic pathways. Science 2004; 305:1163-1167. (Pubitemid 39100331)
6. Wilhelm S, Carter C, Lynch M, Lowinger T, Dumas J, Smith RA et al. Discovery and development of sorafenib: a multikinase inhibitor for treating cancer. Nat Rev Drug Discov 2006; 5:835-844. (Pubitemid 44480537)
7. Wilhelm SM, Adnane L, Newell P, Villanueva A, Llovet JM, Lynch M. Preclinical overview of sorafenib, a multikinase inhibitor that targets both Raf and VEGF and PDGF receptor tyrosine kinase signaling. Mol Cancer Ther 2008; 7:3129-3140.
8. Yu C, Bruzek LM, Meng XW, Gores GJ, Carter CA, Kaufmann SH et al. The role of Mcl-1 downregulation in the proapoptotic activity of the multikinase inhibitor BAY 43-9006. Oncogene 2005; 24:6861-6869. (Pubitemid 41509409)
9. Rahmani M, Davis EM, Bauer C, Dent P, Grant S. Apoptosis induced by the kinase inhibitor BAY 43-9006 in human leukemia cells involves down-regulation of Mcl-1 through inhibition of translation. J Biol Chem 2005; 280:35217-35227. (Pubitemid 41532709)
10. Liu L, Cao Y, Chen C, Zhang X, McNabola A, Wilkie D et al. Sorafenib blocks the RAF/MEK/ERK pathway, inhibits tumor angiogenesis, and induces tumor cell apoptosis in hepatocellular carcinoma model PLC/PRF/5. Cancer Res 2006; 66:11851-11858. (Pubitemid 46094197)
11. Yu J, Zhang L. PUMA, a potent killer with or without p53. Oncogene 2008; 27 (Suppl 1): S71-S83.
12. Yu J, Yue W, Wu B, Zhang L. PUMA sensitizes lung cancer cells to chemotherapeutic agents and irradiation. Clin Cancer Res 2006; 12:2928-2936.
13. Dudgeon C, Wang P, Sun X, Peng R, Sun Q, Yu J et al. PUMA induction by FoxO3a mediates the anticancer activities of the broad-range kinase inhibitor UCN-01. Mol Cancer Ther 2010; 9:2893-2902.
14. Sun Q, Ming L, Thomas SM, Wang Y, Chen ZG, Ferris RL et al. PUMA mediates EGFR tyrosine kinase inhibitor-induced apoptosis in head and neck cancer cells. Oncogene 2009; 18:2348-2357.
15. Wang P, Qiu W, Dudgeon C, Liu H, Huang C, Zambetti GP et al. PUMA is directly activated by NF-kappaB and contributes to TNF-alpha-induced apoptosis. Cell Death Differ 2009; 16:1192-1202.
16. Ming L, Sakaida T, Yue W, Jha A, Zhang L, Yu J. Sp1 and p73 Activate PUMA Following Serum Starvation. Carcinogenesis 2008; 29:1878-1884.
17. Ming L, Wang P, Bank A, Yu J, Zhang L. PUMA dissociates Bax and BCL-XL to induce apoptosis in colon cancer cells. J Biol Chem 2006; 281:16034-16042. (Pubitemid 43848497)
18. Yu J, Wang P, Ming L, Wood MA, Zhang L. SMAC/Diablo mediates the proapoptotic function of PUMA by regulating PUMA-induced mitochondrial events. Oncogene 2007; 26:4189-4198. (Pubitemid 46975795)
19. Yu J, Wang Z, Kinzler KW, Vogelstein B, Zhang L. PUMA mediates the apoptotic response to p53 in colorectal cancer cells. Proc Natl Acad Sci USA 2003; 100:1931-1936. (Pubitemid 36254551)
20. Wilhelm SM, Carter C, Tang L, Wilkie D, McNabola A, Rong H et al. BAY 43-9006 exhibits broad spectrum oral antitumor activity and targets the RAF/MEK/ERK pathway and receptor tyrosine kinases involved in tumor progression and angiogenesis. Cancer Res 2004; 64:7099-7109. (Pubitemid 39331023)
21. Plastaras JP, Kim SH, Liu YY, Dicker DT, Dorsey JF, McDonough J et al. Cell cycle dependent and schedule-dependent antitumor effects of sorafenib combined with radiation. Cancer Res 2007; 67:9443-9454. (Pubitemid 47535934)
22. You H, Pellegrini M, Tsuchihara K, Yamamoto K, Hacker G, Erlacher M et al. FOXO3a-dependent regulation of Puma in response to cytokine/growth factor withdrawal. J Exp Med 2006; 203:1657-1663. (Pubitemid 44036270)
23. Huang S, Sinicrope FA. Sorafenib inhibits STAT3 activation to enhance TRAIL-mediated apoptosis in human pancreatic cancer cells. Mol Cancer Ther 2010; 9:742-750.
24. Baud V, Karin M. Is NF-kappaB a good target for cancer therapy? Hopes and pitfalls. Nat Rev Drug Discov 2009; 8:33-40.
25. Cross DA, Alessi DR, Cohen P, Andjelkovich M, Hemmings BA. Inhibition of glycogen synthase kinase-3 by insulin mediated by protein kinase B. Nature 1995; 378:785-789. (Pubitemid 26004411)
26. Ding Q, Xia W, Liu JC, Yang JY, Lee DF, Xia J et al. Erk associates with and primes GSK-3beta for its inactivation resulting in upregulation of beta-catenin. Mol Cell 2005; 19:159-170. (Pubitemid 41019664)
27. Zhang L, Ming L, Yu J. BH3 mimetics to improve cancer therapy; mechanisms and examples. Drug Resist Updat 2007; 10:207-217. (Pubitemid 351163146)
28. Wilhelm S, Chien DS. BAY 43-9006: preclinical data. Curr Pharm Des 2002; 8:2255-2257. (Pubitemid 35189898)
29. Clark JW, Eder JP, Ryan D, Lathia C, Lenz HJ. Safety and pharmacokinetics of the dual action Raf kinase and vascular endothelial growth factor receptor inhibitor, BAY 43-9006, in patients with advanced, refractory solid tumors. Clin Cancer Res 2005; 11:5472-5480. (Pubitemid 41060823)
30. Opferman JT, Iwasaki H, Ong CC, Suh H, Mizuno S, Akashi K et al. Obligate role of anti-apoptotic MCL-1 in the survival of hematopoietic stem cells. Science 2005; 307:1101-1104. (Pubitemid 40262114)
31. Zhang W, Konopleva M, Ruvolo VR, McQueen T, Evans RL, Bornmann WG et al. Sorafenib induces apoptosis of AML cells via Bim-mediated activation of the intrinsic apoptotic pathway. Leukemia 2008; 22:808-818. (Pubitemid 351552630)
32. Dutta J, Fan Y, Gupta N, Fan G, Gelinas C. Current insights into the regulation of programmed cell death by NF-kappaB. Oncogene 2006; 25:6800-6816. (Pubitemid 44657853)
33. Biton S, Ashkenazi A. NEMO and RIP1 control cell fate in response to extensive DNA damage via TNF-alpha feedforward signaling. Cell 2011; 145:92-103.
34. Augustine CK, Toshimitsu H, Jung SH, Zipfel PA, Yoo JS, Yoshimoto Y et al. Sorafenib, a multikinase inhibitor, enhances the response of melanoma to regional chemotherapy. Mol Cancer Ther 2010; 9:2090-2101.
35. Sun W, Powell M, O'Dwyer PJ, Catalano P, Ansari RH, Benson III AB. Phase II study of sorafenib in combination with docetaxel and cisplatin in the treatment of metastatic or advanced gastric and gastroesophageal junction adenocarcinoma: ECOG 5203. J Clin Oncol 2010; 28:2947-2951.
36. Kim C, Lee JL, Choi YH, Kang BW, Ryu MH, Chang HM et al. Phase I dose-finding study of sorafenib in combination with capecitabine and cisplatin as a first-line treatment in patients with advanced gastric cancer. Invest New Drugs 2010 (e-pub ahead of print 14 September 2010).
37. Molhoek KR, Brautigan DL, Slingluff Jr CL. Synergistic inhibition of human melanoma proliferation by combination treatment with B-Raf inhibitor BAY43-9006 and mTOR inhibitor rapamycin. J Transl Med 2005; 3:39.
38. Martinelli E, Troiani T, Morgillo F, Rodolico G, Vitagliano D, Morelli MP et al. Synergistic antitumor activity of sorafenib in combination with epidermal growth factor receptor inhibitors in colorectal and lung cancer cells. Clin Cancer Res 2010; 16:4990-5001.
39. Lind JS, Dingemans AM, Groen HJ, Thunnissen FB, Bekers O, Heideman DA et al. A multicenter phase II study of erlotinib and sorafenib in chemotherapy-naive patients with advanced non-small cell lung cancer. Clin Cancer Res 2010; 16:3078-3087.
40. Hong DS, Sebti SM, Newman RA, Blaskovich MA, Ye L, Gagel RF et al. Phase I trial of a combination of the multikinase inhibitor sorafenib and the farnesyltransferase inhibitor tipifarnib in advanced malignancies. Clin Cancer Res 2009; 15:7061-7068.
41. Gomez-Benito M, Marzo I, Anel A, Naval J. Farnesyltransferase inhibitor BMS-214662 induces apoptosis in myeloma cells through PUMA up-regulation, Bax and Bak activation, and Mcl-1 elimination. Mol Pharmacol 2005; 67:1991-1998. (Pubitemid 41007780)
42. Zhang G, Park MA, Mitchell C, Hamed H, Rahmani M, Martin AP et al. Vorinostat and sorafenib synergistically kill tumor cells via FLIP suppression and CD95 activation. Clin Cancer Res 2008; 14:5385-5399.
43. Martin AP, Park MA, Mitchell C, Walker T, Rahmani M, Thorburn A et al. BCL-2 family inhibitors enhance histone deacetylase inhibitor and sorafenib lethality via autophagy and overcome blockade of the extrinsic pathway to facilitate killing. Mol Pharmacol 2009; 76:327-341.
44. Hikita H, Takehara T, Shimizu S, Kodama T, Shigekawa M, Iwase K et al. The Bcl-xL inhibitor, ABT-737, efficiently induces apoptosis and suppresses growth of hepatoma cells in combination with sorafenib. Hepatology 2010; 52:1310-1321.
45. Chen KF, Chen HL, Tai WT, Feng WC, Hsu CH, Chen PJ et al. Activation of PI3K/Akt signaling pathway mediates acquired resistance to sorafenib in hepatocellular carcinoma cells. J Pharmacol Exp Ther 2011; 337:155-161.
46. Gedaly R, Angulo P, Hundley J, Daily MF, Chen C, Koch A et al. PI-103 and sorafenib inhibit hepatocellular carcinoma cell proliferation by blocking Ras/Raf/MAPK and PI3K/AKT/mTOR pathways. Anticancer Res 2010; 30:4951-4958.
47. Wang P, Yu J, Zhang L. The nuclear function of p53 is required for PUMA-mediated apoptosis induced by DNA damage. Proc Natl Acad Sci USA 2007; 104:4054-4059. (Pubitemid 47181577)
48. Yue W, Sun Q, Dacic S, Landreneau RJ, Siegfried JM, Yu J et al. Downregulation of Dkk3 activates beta-catenin/TCF-4 signaling in lung cancer. Carcinogenesis 2008; 29:84-92. (Pubitemid 351201745)
49. Kohli M, Yu J, Seaman C, Bardelli A, Kinzler KW, Vogelstein B et al. SMAC/Diablo-dependent apoptosis induced by nonsteroidal antiinflammatory drugs (NSAIDs) in colon cancer cells. Proc Natl Acad Sci USA 2004; 101:16897-16902. (Pubitemid 39601335)
50. Li H, Wang P, Sun Q, Ding WX, Yin XM, Sobol RW et al. Following cytochrome c release, autophagy is inhibited during chemotherapy-induced apoptosis by caspase 8-mediated cleavage of Beclin 1. Cancer Res 2011; 71:3625-3634.
51. Qiu W, Wang X, Leibowitz B, Liu H, Barker N, Okada H et al. Chemoprevention by nonsteroidal anti-inflammatory drugs eliminates oncogenic intestinal stem cells via SMAC-dependent apoptosis. Proc Natl Acad Sci USA 2010; 107:20027-20032.